News in Brief
Health - Feb 26
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
Pharmacology - Feb 26
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Pharmacology - Feb 26
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Health - Feb 26
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Administration - Feb 25
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024
wire - news in brief
Category
--
Results 151 - 200 of 437.
Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In
Civil society and governments struggle to take action when it comes to climate change. So what's the solution? We asked climate researcher Reto Knutti and climate strike advocate Marie-Claire Graf for their perspectives.
Ticino Scienza, the news portal to "explain excellence"
Over the past two decades the Italian-speaking part of Switzerland has witnessed a strong rise in scientific research activities, both in the private and the public sector.
Over the past two decades the Italian-speaking part of Switzerland has witnessed a strong rise in scientific research activities, both in the private and the public sector.
Pretend play promotes the development of socio-emotional competences in children aged five and six. Being socially and emotionally competent from an early age is likely to help children win acceptance by their peers, build better relationships with teachers, and facilitate academic learning.
The University of Bern has set itself the goal of becoming a climate-neutral institution by 2025 in all areas in which it has a direct influence.
Can we "repair" criminal justice?
Passing a law, committing a crime, inflicting a sanction. These are the main the stages of criminal justice at the heart of modern legal systems.
Passing a law, committing a crime, inflicting a sanction. These are the main the stages of criminal justice at the heart of modern legal systems.
Foundations for the energy system of tomorrow
On the road to a sustainable energy system, technologies for the flexible conversion and efficient storage of energy are becoming increasingly important.
On the road to a sustainable energy system, technologies for the flexible conversion and efficient storage of energy are becoming increasingly important.
On the road to a sustainable energy system, technologies for the flexible conversion and efficient storage of energy are becoming increasingly important.
The COVID-19 pandemic is putting Swiss crisis management to the test. ETH Professor Andreas Wenger and his team from the Center for Security Studies have investigated in detail how well Switzerland coped with the first phase of the crisis.
A team at Balgrist University Hospital successfully completed the first holographically navigated spine surgery.
Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infection Roche will be able to ramp up to a double-digit million number
The Engineering Humanitarian Aid initiative, officially launched on 10 December 2020, will harness the expertise of Switzerland's two federal institutes of technology to benefit humanitarian aid programs.
The Engineering Humanitarian Aid initiative, officially launched on 10 December 2020, will harness the expertise of Switzerland's two federal institutes of technology to benefit humanitarian aid programs.
The coronavirus is not only a risk for our physical health, but also affects our mental health and emotional well-being.
Novartis Kisqali demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with un rivaled OS evidence 1 Kisqali plus endocrine therapy had a median OS of nearly five years (58&peri
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with un rivaled OS evidence 1 Kisqali plus endocrine therapy had a median OS of nearly five years (58&peri
The Graphische Sammlung opened a new exhibition on 9 December. What makes this latest exhibition special is its integration with an augmented reality app for mobile phones and tablets, which allows visitors to interact with the artwork on display.
Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine tri
Moderna's vaccine triggers an antibody response to the SARS-CoV-2 spike protein The Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine tri
At NEST, the research and innovation platform of Empa and Eawag, a new unit is currently being planned: STEP2.
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif * in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibito
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibito
COVID-19: persistent symptoms in one third of cases
Physicians in Geneva have shown that some of the troublesome symptoms of COVID-19 could last more than 6 weeks, even in patients without underlying risk factors.
Physicians in Geneva have shown that some of the troublesome symptoms of COVID-19 could last more than 6 weeks, even in patients without underlying risk factors.
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers
Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, an
Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, an
Novartis analyses confirm benefit of Kymriah with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83% 1 L
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83% 1 L
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic
Strong and resilient supply chains ensure the provision of quality health products and vaccines to patients, making them a central component of health systems.
ETH Zurich supports art in construction, and, as part of a project competition, has selected art projects by Maya Rochat and Yves Netzhammer that take an innovative approach to reflecting on teaching and research in the two ETH buildings BSS and ML-FHK.
Natural Selection also Increases the Adaptability of Organism
Natural selection causes organisms to adapt continuously. Researchers at the University of Zurich now show for the first time that proteins in bacteria develop a new property more rapidly when the selection pressure is high. Natural selection can thus also increase the evolutionary capacity itself.
Natural selection causes organisms to adapt continuously. Researchers at the University of Zurich now show for the first time that proteins in bacteria develop a new property more rapidly when the selection pressure is high. Natural selection can thus also increase the evolutionary capacity itself.
News in Brief
Health - Feb 26
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
Pharmacology - Feb 26
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
Pharmacology - Feb 26
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Health - Feb 26
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Administration - Feb 25
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024
Federal bilateral programmes for cooperation in research and innovation with non-European partner countries 2021-2024